latest news releases from the newsroom
Total Identity Corp. Adds New CFO and COO
ROCHESTER, N.Y., June 23, 2004 (PRIMEZONE) -- Total Identity Corp. ("TIC") (OTCBB:TIDC) is pleased to announce that that Jeffrey Hoffman has joined the company as its new CFO and COO full-time. Mr. Hoffman was a consultant for the company during part of the 4th Quarter 2003 to assist TIC with its purchase of Total Identity Systems Corp. ("TIS"). Mr. Hoffman will ensure that TIC has the proper financial controls and corporate governance policies in place. In addition, Mr. Hoffman will work to ensure that TIC makes its financial filings in a timely manner and to reduce its overall auditing and review expenses.
Changes in Sandvik's Group Executive Management
SANDVIKEN, Sweden, June 23, 2004 (PRIMEZONE) -- Anders Ilstam, Executive Vice President, Sandvik AB, has chosen to exercise the possibility to retire at age 62 and is leaving his position on 1 July 2004. Ilstam has been employed by the company since 1993 and during the period 1998-2003 was President of the Sandvik Mining and Construction business area.
Kristina Schauman New Chief Financial Officer of OMHEX
STOCKHOLM, Sweden, June 23, 2004 (PRIMEZONE) -- OMHEX has today appointed Kristina Schauman as new Chief Financial Officer (CFO) of OMHEX. Kristina will replace Per Nordberg, who will leave the company to become Executive Vice President and CFO of Sandvik AB.
Celltech Group plc
Celltech Announces U.S. FDA Approval For 12-Hour Codeprex
SLOUGH, U.K., June 23, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announces that the U.S. Food and Drug Administration ("FDA") has approved Codeprex(tm) (codeine polistirex/ chlorpheniramine polistirex) Extended-Release Suspension CIII for cough relief. Codeprex(tm) uses Celltech's proprietary Pennkinetic(r) extended-release drug delivery technology to provide 12-hour dosing. Codeprex(tm) is the first codeine-based cough suppressant to provide 12-hour dosing and offers patients the convenience of less frequent dosing compared to other codeine cough suppressants, in particular by avoiding the need for middle of the night dosing.